About: Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	We analyzed proliferative index of myeloma plasmocytes (PC-PI) in a cohort of 217 patients with multiple myeloma (MM) treated with conventional chemotherapy and biological agents, thalidomide and bortezomib. In the whole group was a difference between overall survival (OS) favoring patients with PC-PI<2,8% (median overall survival 30 vs 12 months) with a borderline significance (p=0,06). However, after approximately 40 months from diagnosis the curves merged, suggesting the influence of novel drugs. In patients treated with conventional chemotherapy only, the difference maintained significant even after 40 months (median overall survival 25 vs 10 months, p=0,015), whereas in the group treated with thalidomide and bortezomib was no difference, with medians over 39 months. Even patients with low PC-PI profited from the treatment with novel drugs. Presented results suggest that the treatment of MM with novel agents overcomes the prognostic significance of PC-PI and should be used in all MM patients. We analyzed proliferative index of myeloma plasmocytes (PC-PI) in a cohort of 217 patients with multiple myeloma (MM) treated with conventional chemotherapy and biological agents, thalidomide and bortezomib. In the whole group was a difference between overall survival (OS) favoring patients with PC-PI<2,8% (median overall survival 30 vs 12 months) with a borderline significance (p=0,06). However, after approximately 40 months from diagnosis the curves merged, suggesting the influence of novel drugs. In patients treated with conventional chemotherapy only, the difference maintained significant even after 40 months (median overall survival 25 vs 10 months, p=0,015), whereas in the group treated with thalidomide and bortezomib was no difference, with medians over 39 months. Even patients with low PC-PI profited from the treatment with novel drugs. Presented results suggest that the treatment of MM with novel agents overcomes the prognostic significance of PC-PI and should be used in all MM patients. (en)
Title	Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma (en)
skos:prefLabel	Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma (en)
skos:notation	RIV/00098892:_____/10:#0000398!RIV13-MZ0-00098892
http://linked.open...avai/riv/aktivita	P
http://linked.open...avai/riv/aktivity	P(NR9500)
http://linked.open...iv/cisloPeriodika	1
http://linked.open...vai/riv/dodaniDat	2013
http://linked.open...aciTvurceVysledku	Zemanová, Markéta
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Fakultní nemocnice Olomouc
http://linked.open...dnocenehoVysledku	292619
http://linked.open...ai/riv/idVysledku	RIV/00098892:_____/10:#0000398
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	myeloma, prognostication, proliferative index, biological therapy (en)
http://linked.open.../riv/klicoveSlovo	proliferative index myeloma biological therapy prognostication
http://linked.open...odStatuVydavatele	SK - Slovenská republika
http://linked.open...ontrolniKodProRIV	[07E79F025D92]
http://linked.open...i/riv/nazevZdroje	Neoplasma
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	7 (xsd:int)
http://linked.open...vavai/riv/projekt	Angiogenesis, plasma cell kinetics, parameters of microenvironments of bone marrow and bone metabolism in monoclonal gammopathy of undetermined significance and initial phases of multiple myeloma
http://linked.open...UplatneniVysledku	2010
http://linked.open...v/svazekPeriodika	57
http://linked.open...iv/tvurceVysledku	Minařík, Jiří Zemanová, Markéta
issn	0028-2685
number of pages	7 (xsd:int)

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 82 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software